Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
Akero Therapeutics Inc (NASDAQ: AKRO) closed the day trading at $44.78 up 2.87% from the previous closing price of $43.53. In other words, the price has increased by $2.87 from its previous closing price. On the day, 0.74 million shares were traded. AKRO stock price reached its highest trading level at $44.91 during the session, while it also had its lowest trading level at $42.9.
Ratios:
For a better understanding of AKRO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 19.38 and its Current Ratio is at 19.38. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on January 30, 2025, Upgraded its rating to Buy and sets its target price to $63 from $35 previously.
On January 27, 2025, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $50 to $72.
On November 18, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $65.Citigroup initiated its Buy rating on November 18, 2024, with a $65 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 17 ’25 when Yale Catriona sold 10,000 shares for $44.76 per share. The transaction valued at 447,605 led to the insider holds 95,034 shares of the business.
Cheng Andrew sold 1,738 shares of AKRO for $78,001 on Mar 12 ’25. The President and CEO now owns 654,324 shares after completing the transaction at $44.88 per share. On Mar 12 ’25, another insider, Young Jonathan, who serves as the Chief Operating Officer of the company, sold 607 shares for $44.88 each. As a result, the insider received 27,242 and left with 200,540 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 3565387776 and an Enterprise Value of 2858428416.
Stock Price History:
The Beta on a monthly basis for AKRO is -0.21, which has changed by 0.7262914 over the last 52 weeks, in comparison to a change of 0.08275449 over the same period for the S&P500. Over the past 52 weeks, AKRO has reached a high of $58.40, while it has fallen to a 52-week low of $17.86. The 50-Day Moving Average of the stock is 4.79%, while the 200-Day Moving Average is calculated to be 43.33%.
Shares Statistics:
Over the past 3-months, AKRO traded about 1.32M shares per day on average, while over the past 10 days, AKRO traded about 931650 shares per day. A total of 72.38M shares are outstanding, with a floating share count of 70.68M. Insiders hold about 11.23% of the company’s shares, while institutions hold 86.18% stake in the company. Shares short for AKRO as of 1740700800 were 5052816 with a Short Ratio of 3.83, compared to 1738281600 on 3628575. Therefore, it implies a Short% of Shares Outstanding of 5052816 and a Short% of Float of 6.510000000000001.
